Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

• Published in: Clinical cancer research 2021-08, Vol.27 (15), p.4397-4409
• Main Authors: Kim, Seok-Young, Kim, Sang-Min, Lim, Sumin, Lee, Ji Yeon, Choi, Su-Jin, Yang, San-Duk, Yun, Mi Ran, Kim, Chang Gon, Gu, Seo Rin, Park, Chaewon, Park, A-Young, Lim, Sun Min, Heo, Seong Gu, Kim, HyunKi, Cho, Byoung Chul
• Format: Article
• Language: English
• Subjects: Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - pathology; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Models, Biological; Neoplasm Staging; Organoids - drug effects; Translational Cancer Mechanisms and Therapy
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.ccr-20-5026

Patient-derived organoids (PDO) of lung cancer has been recently introduced, reflecting the genomic landscape of lung cancer. However, clinical relevance of advanced lung adenocarcinoma organoids remains unknown. Here, we examined the ability of PDOs to predict clinical responses to targeted therapies in individual patients and to identify effective anticancer therapies for novel molecular targets. Eighty-four organoids were established from patients with advanced lung adenocarcinoma. Formalin-fixed, paraffin-embedded tumor specimens from corresponding patients were analyzed by whole-exome sequencing ( = 12). Organoids were analyzed by whole-exome sequencing ( = 61) and RNA sequencing ( = 55). Responses to mono or combination targeted therapies were examined in organoids and organoid-derived xenografts. PDOs largely retained somatic alterations including driver mutations of matching patient tumors. PDOs were able to recapitulate progression-free survival and objective responses of patients with non-small cell lung cancer receiving clinically approved tyrosine kinase inhibitors. PDOs recapitulated activity of therapeutic strategies under clinical investigation. YUO-071 harboring an exon 19 deletion and a G464A mutation and the matching patient responded to dabrafenib/trametinib combination therapy. YUO-004 and YUO-050 harboring an L747P mutation was sensitive to afatinib, consistent with the response in the matching patient of YUO-050. Furthermore, we utilized organoids to identify effective therapies for novel molecular targets by demonstrating the efficacy of poziotinib against exon 20 insertions and pralsetinib against fusions. We demonstrated translational relevance of PDOs in advanced lung adenocarcinoma. PDOs are an important diagnostic tool, which can assist clinical decision making and accelerate development of therapeutic strategies.